COMMUNIQUÉS West-GlobeNewswire

Malaysia Healthcare Travel Council Denies Allegations of Lack Of Direction in the Company

02/03/2024 - 06:22

KUALA LUMPUR, Malaysia, March 02, 2024 (GLOBE NEWSWIRE) -- Malaysia Healthcare Travel Council (MHTC) would like to refer to the news published by a local news organisation titled - “Malaysia Healthcare Travel Council in [...]

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

02/03/2024 - 01:00

CHARLOTTESVILLE, Va., March 01, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the [...]

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

02/03/2024 - 00:04

Company Announcement COPENHAGEN, Denmark; March 02, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02/03/2024 - 00:00

NEW YORK & SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small [...]

MacroGenics to Participate in Upcoming Investor Conferences

01/03/2024 - 23:48

ROCKVILLE, MD, March 01, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics [...]

ICU Medical to Present at the Raymond James 45ᵗʰ Annual Institutional Investors Conference

01/03/2024 - 23:15

SAN CLEMENTE, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will [...]

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01/03/2024 - 23:08

DALLAS, March 01, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe [...]

Iovance Biotherapeutics to Present at Upcoming Conferences

01/03/2024 - 23:00

SAN CARLOS, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/03/2024 - 23:00

SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]

BioVie Inc. Announces Proposed Public Offering of Common Stock

01/03/2024 - 22:58

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and [...]

LeMaitre to Participate at Upcoming Investor Conferences in March

01/03/2024 - 22:37

BURLINGTON, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in four upcoming investor conferences in March. Oppenheimer 34 th Annual [...]

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01/03/2024 - 22:30

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/03/2024 - 22:20

RESEARCH TRIANGLE PARK, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 [...]

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01/03/2024 - 22:16

REDWOOD CITY, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent [...]

Merus annonce ses résultats financiers pour le quatrième trimestre 2023 ainsi que pour l’ensemble de l’exercice 2023 et fait le point sur ses activités

01/03/2024 - 22:15

– Présentation des données cliniques intermédiaires préliminaires pour le pétosemtamab en association avec le pembrolizumab en 1 re ligne de traitement dans le carcinome épidermoïde de la tête et du coup (« CETC ») [...]

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

01/03/2024 - 22:05

SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine [...]

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/03/2024 - 22:05

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on February 29, 2024 [...]

NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit

01/03/2024 - 22:04

TORONTO and HAIFA, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is pleased to announce that Dr. Ina [...]

Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

01/03/2024 - 22:01

WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for [...]